Squawk on the Street cover image

Trump's Tariff Threat, Retail Earnings Ahead of Black Friday, Amgen Tumbles on Weight-Loss Drug Data 11/26/24

Squawk on the Street

00:00

Amgen's Weight Loss Drug Woes

This chapter examines Amgen's declining stock performance linked to concerns over its experimental weight loss drug and its mixed results in trials. It also discusses the broader market implications of the Biden administration's efforts to expand access to obesity treatments and the volatility in futures trading.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app